- Revenue 2024
- $2,055,218
- Expenses 2024
- $1,833,664
Program services were 86.3% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.
As filed
- Subsection
- 03
- NTEE code
- H30
- Classification
- 1800
- Street
- 2451 CROASDAILE FARM PKWY STE 109
These codes are the IRS's own and are shown exactly as filed. What each one means is in the Business Master File documentation (opens in a new tab).
Mission and programs · 2024
Mission
THE GLIOBLASTOMA FOUNDATION IS DEDICATED TO FINDING A CURE FOR GLIOBLASTOMA BY FUNDING RESEARCH AND DRUG DEVELOPMENT, SUPPORTING PATIENTS AND FAMILIES, AND RAISING NATIONAL AWARENESS OF THIS DEVASTATING BRAIN CANCER. THROUGH THESE INTEGRATED PROGRAMS, THE FOUNDATION ACCELERATES SCIENTIFIC DISCOVERY, EMPOWERS PATIENTS WITH INFORMATION AND RESOURCES, AND EDUCATES THE PUBLIC ABOUT THE URGENT NEED FOR BETTER TREATMENTS AND IMPROVED OUTCOMES.
Activities or mission (Part I)
TO IMPROVE TREATMENT OPTIONS FOR GLIOBLASTOMA PATIENTS BY FUNDING INNOVATIVE RESEARCH, EXPANDING ACCESS TO GENOMIC TESTING, SUPPORTING PATIENTS AND FAMILIES, AND RAISING NATIONAL AWARENESS OF THIS AGGRESSIVE BRAIN CANCER.
-
RESEARCH AND DRUG DEVELOPMENT:IN 2024, THE GLIOBLASTOMA FOUNDATION ADVANCED ITS RESEARCH MISSION BY ACQUIRING LISAVANBULIN, A PROMISING TARGETED THERAPY FROM BASILEA PHARMACEUTICA, FOR FURTHER CLINICAL DEVELOPMENT IN GLIOBLASTOMA. THIS ACQUISITION MARKED A CRITICAL STEP TOWARD BRINGING PATIENTS NEW, MORE EFFECTIVE TREATMENTS. THE FOUNDATION ALSO SUPPORTED INVESTIGATOR-INITIATED RESEARCH ON MOLECULAR CHARACTERIZATION AND FUNCTIONAL PRECISION ONCOLOGY. ADDITIONALLY, THE FOUNDATION ESTABLISHED GLIOLAB, A CLIA-REGISTERED GENOMIC LABORATORY THAT WILL PROVIDE STATE-OF-THE-ART TESTING TO ACCELERATE DISCOVERY OF TARGETED THERAPIES BASED ON EACH TUMOR'S GENOMIC AND EPIGENOMIC PROFILE.
Expenses $527,251 · Grants $97,474
-
PATIENT SUPPORT AND EDUCATION:THROUGHOUT 2024, THE FOUNDATION PROVIDED SUPPORT SERVICES FOR GLIOBLASTOMA PATIENTS AND CAREGIVERS NATIONWIDE, INCLUDING PERSONALIZED CLINICAL-TRIAL MATCHING, PROFESSIONALLY LED VIRTUAL SUPPORT GROUPS, AND EDUCATIONAL RESOURCES ON TREATMENT OPTIONS AND EMERGING RESEARCH. THESE PROGRAMS EMPOWERED PATIENTS TO MAKE INFORMED CARE DECISIONS AND FOSTERED A SENSE OF COMMUNITY AMONG FAMILIES AFFECTED BY THIS RARE DISEASE. HUNDREDS OF PATIENTS AND CAREGIVERS BENEFITED FROM THESE FREE SERVICES DURING THE YEAR.
Expenses $527,251
-
PUBLIC AWARENESS AND ADVOCACY:THE FOUNDATION LED NATIONWIDE EFFORTS TO RAISE AWARENESS AND ADVOCACY FOR THOSE AFFECTED BY GLIOBLASTOMA. IN 2024, IT ORGANIZED GLIOBLASTOMA AWARENESS DAY AND CONTINUED THE VOICES OF GLIOBLASTOMA PODCAST WHILE PLANNING TO EXPAND THE SERIES IN FUTURE YEARS TO FEATURE ADDITIONAL PATIENT, CAREGIVER, AND SCIENTIST PERSPECTIVES. THE FOUNDATION ALSO PARTNERED WITH EVENTS SUCH AS THE LOS ANGELES MARATHON TO INCREASE PUBLIC UNDERSTANDING AND SUPPORT FOR RESEARCH. THESE INITIATIVES EDUCATED THOUSANDS AND INSPIRED HOPE WITHIN THE GLIOBLASTOMA COMMUNITY.
Expenses $527,250
As filed on the 2024 return. The filer continues this part on Schedule O, which is not shown here.
Officers and directors · 2024
As listed in Part VII of the 2024 return, in the order the filer printed them. Each return names its own; this is not a roster the organization keeps with us.
-
Neelam KwatraNEELAM KWATRA
PRESIDENT
- Total calculated
- $0
- Hours/week
- 20
-
Madan KwatraMADAN KWATRA
TREASURER/SECRETARY
- Total calculated
- $0
- Hours/week
- 4
-
Gita KwatraGITA KWATRA
CEO
- Total calculated
- $343,048
- From this org
- $291,500
- From related orgs
- $0
- Other
- $51,548
- Hours/week
- 40
Schedule J breakdown matched by us
- Base
- $291,500
- Bonus
- $0
- Other
- $0
- Deferred
- $23,000
- Nontaxable benefits
- $28,548
- Filer's total
- $343,048
-
Cameron WestCAMERON WEST
BOARD MEMBER
- Total calculated
- $0
- Hours/week
- 1
-
Brian AustinBRIAN AUSTIN
BOARD MEMBER
- Total calculated
- $0
- Hours/week
- 1
Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us. Earlier years are each on their own filing page.
Filings
-
2024
- Revenue
- $2,055,218
- Expenses
- $1,833,664
- Contributions
- $1,964,537
- Grants paid
- $97,474
-
2023
- Revenue
- $1,699,784
- Expenses
- $1,411,492
- Contributions
- $1,691,690
- Grants paid
- $245,000
-
2022
- Revenue
- $1,471,550
- Expenses
- $853,578
- Contributions
- $1,513,382
- Grants paid
- $180,000
The four totals the IRS asks for on Part I of the Form 990, as filed. A dash means the figure was not present on the return — not that it was zero.
Other returns filed
-
2021 · 990
- Revenue
- $1,253,574
- Expenses
- $703,351
- Assets (EOY)
- $1,523,936
-
2020 · 990
- Revenue
- $958,672
- Expenses
- $323,928
- Assets (EOY)
- $1,140,681
-
2019 · 990
- Revenue
- $448,677
- Expenses
- $296,591
- Assets (EOY)
- $455,940
Nonprofiteer parses Forms 990, 990-EZ and 990-PF, in a window of recent tax years. These returns are recorded from the IRS e-file index, so their figures were extracted by that index rather than read from the return here — treat them as a different source from the filings above, not as more of the same record. A dash means the index carries no figure; Form 990-T listings carry none at all.
Grants made
-
2023 GLIOBLASTOMA RESEARCH
-
$90,000
2022 GLIOBLASTOMA RESEARCH
-
$75,000
2023 GLIOBLASTOMA RESEARCH
-
2024 GLIOBLASTOMA RESEARCH
-
2022 GLIOBLASTOMA RESEARCH
-
THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER
$40,000
2022 GLIOBLASTOMA RESEARCH
-
$30,000
2023 GLIOBLASTOMA RESEARCH
-
$30,000
2023 GLIOBLASTOMA RESEARCH
-
$17,685
2024 GLIOBLASTOMA RESEARCH
-
$11,566
2024 GLIOBLASTOMA RESEARCH
The 10 largest by cash amount. The API serves every itemized grant.
Grants received
-
$346,232
2024 GENERAL SUPPORT
-
$174,643
2023
-
2024 For grant recipient's exempt purposes
-
2023 For grant recipient's exempt purposes
-
2023 GENERAL SUPPORT
-
2022 GENERAL SUPPORT
-
2022 For grant recipient's exempt purposes
-
2024 GENERAL SUPPORT
-
2024 General Support
-
$22,568
2022 GENERAL SUPPORT
The 10 largest by cash amount. The API serves every itemized grant.
Other IRS files
Auto-Revocation List
Not listed. The IRS publishes this list for organizations whose exemption was automatically revoked for failing to file for three consecutive years.
Publication 78
Listed as of 13 October 2026, under deductibility PC.
These are two separate IRS files on two separate schedules, shown as published and not reconciled with each other. Neither is a statement about whether a contribution is deductible today: 19,245 organizations appear in Publication 78 while the IRS's own revocation file lists them as currently revoked, more than half of those revoked before 2019. Absence from Publication 78 is evidence of nothing, and presence is not evidence either. Verify current status with the IRS before relying on it.
What this page reflects
The registration facts above come from the IRS Business Master File published 13 October 2026 and read 1 November 2026, for every organization at once. Returns through tax year 2024, the newest we have parsed for this organization.